Rituximab in chronic inflammtory demyelinating polyneuropathy associated with diabetes mellitus

Background: Some patients with diabetes mellitus (DM) develop a peripheral neuropathy indistinguishable from chronic demyelinating polyneuropathy (CIDP). Immune-mediated mechanisms are involved in the pathogenesis of demyelinating neuropathy in DM and in CIDP. Immunotherapy, including intravenous immunoglobulin (IVIg) is effective in idiopathic CIDP and CIDP-DM. Despite treatment with IVIg, CIDP may remain clinically active. It has been reported that CIDP may respond to Rituximab (RTX), a chimeric humanized monoclonal antibody against CD20+ antigen on B-lymphocytes. We reported a patient with CIDP associated wit…